Population pharmacokinetics of cisplatin in adult cancer patients

Cancer Chemotherapy and Pharmacology

Volumn 54, Issue 2, 2004, Pages 105-112

  De Jongh, Felix E ^a,b   Gallo, James M ^c   Shen, Meiyu ^c   Verweij, Jaap ^a   Sparreboom, Alex ^a,d  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b IKAZIA HOSPITAL   (Netherlands)

^c FOX CHASE CANCER CENTER   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Cisplatin; Pharmacokinetics; Population model

Indexed keywords

ALBUMIN; ANTINEOPLASTIC AGENT; CISPLATIN; DOCETAXEL; ETOPOSIDE; IRINOTECAN; TOPOTECAN;

ADULT; AGED; ARTICLE; BODY HEIGHT; BODY SURFACE; BODY WEIGHT; CANCER; CLINICAL TRIAL; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; FEMALE; HEMATOCRIT; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEPHROTOXICITY; POPULATION; PRIORITY JOURNAL; SIDE EFFECT; VOMITING;

EID: 3843061295     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-004-0790-5     Document Type: Article

References (31)

1. Akaike H (1976) An information criterion. Math Sci 14:5
2. Erdlenbruch B, Nier M, Kern W, Hiddemann W, Pekrun A, Lakomek M (2001) Pharmacokinetics of cisplatin and relation to nephrotoxicity in paediatric patients. Eur J Clin Pharmacol 57:393
3. Felici A, Verweij J, Sparreboom A (2002) Dosing strategies for anticancer agents: the good, the bad and body-surface area. Eur J Cancer 38:1674
4. Gelderblom AJ, Loos WJ, de Jonge MJA, Sparreboom A, Planting AST, van der Burg MEL, Brouwer E, Verheij C, Ouwens L, Hearn S, Verweij J (2000) Phase I and pharmacological study of increased dose oral topotecan in combination with intravenous cisplatin. Ann Oncol 11:1205
5. Go RS, Adjei AA (1999) Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. J Clin Oncol 17:409
6. Gurney H (1996) Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative. J Clin Oncol 14:2590
7. Hanada K, Ninomiya K, Ogata H (2000) Pharmacokinetics and toxicodynamics of cisplatin and its metabolites in rats: relationship between renal handling and nephrotoxicity of cisplatin. J Pharm Pharmacol 52:1345
8. Hanada K, Nishijima K, Ogata H, Atagi S, Kawahara M (2001) Population pharmacokinetic analysis of cisplatin and its metabolites in cancer patients: possible misinterpretation of covariates for pharmacokinetic parameters calculated from the concentrations of unchanged cisplatin, ultrafiltered platinum and total platinum. Jpn J Clin Oncol 31:179
9. Hastie TJ, Tibshirani RJ (1990) Generalized additive models. Chapman & Hall, London, pp 256-259
10. Hrushesky WJM, Shimp W, Kennedy BJ (1984) Lack of age-dependent cisplatin nephrotoxicity. Am J Med 76:579
11. Ivanov AI, Christodoulou J, Parkinson JA, Barnham KJ, Tucker A, Woodrow J, Sadler PJ (1998) Cisplatin binding sites on human albumin. J Biol Chem 273:14721
12. de Jonge MJA, Verweij J, Planting AST, van der Burg MEL, Stoter G, de Boer-Dennert MM, de Bruijn P, Brouwer E, Vernillet L, Sparreboom A (1999) Drug-administration sequence does not change pharmacodynamics and kinetics of irinotecan and cisplatin. Clin Cancer Res 5:2012
13. de Jonge MJA, Sparreboom A, Planting AST, van der Burg MEL, de Boer-Dennert MM, ter Steeg J, Jacques C, Verweij J (2000) Phase I study of 3-week schedule of irinotecan combined with cisplatin in patients with advanced solid tumors. J Clin Oncol 18:187
14. de Jonge MJA, Verweij J, de Bruijn P, Brouwer E, Mathijssen RHJ, van Alphen RJ, de Boer-Dennert MM, Vernillet L, Jacques C, Sparreboom A (2000) Pharmacokinetic, metabolic, and pharmacodynamic profiles in a dose-escalating study of irinotecan and cisplatin. J Clin Oncol 18:195
15. de Jonge MJA, Loos WJ, Gelderblom AJ, Planting AST, van der Burg MEL, Sparreboom A, Brouwer E, van Beurden V, Mantel MA, Doyle E, Hearn S, Ross G, Verweij J (2000) Phase I pharmacologic study of oral topotecan and intravenous cisplatin: sequence-dependent hematologic side effects. J Clin Oncol 18:2104
16. de Jongh FE, Verweij J, Loos WJ, de Wit R, de Jonge MJA, Planting AST, Nooter K, Stoter G, Sparreboom A (2001) Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposure. J Clin Oncol 19:3733
17. de Jongh FE, van Veen RN, Veltman SJ, de Wit R, van der Burg MEL, van den Bent MJ, Planting AST, Graveland WJ, Stoter G, Verweij J (2003) Weekly high-dose cisplatin is a feasible treatment option: analysis on prognostic factors for toxicity in 400 patients. Br J Cancer 88:1199
18. Ma J, Stoter G, Verweij J, Schellens JHM (1996) Comparison of ethanol plasma-protein precipitation with plasma ultrafiltration and trichloroacetic acid protein precipitation for the measurement of unbound platinum concentrations. Cancer Chemother Pharmacol 38:391
19. Mandema JW, Verotta D, Sheiner LB (1992) Building population pharmacokinetic-pharmacodynamic models. I. Models for covariate effects. J Pharmacokinet Biopharm 20:511
20. Nagai N, Kinoshita M, Ogata H, Tsujino D, Wada Y, Someya K, Ohno T, Masuhara K, Tanaka Y, Kato K, Nagai H, Yokoyama A, Kurita Y (1996) Relationship between pharmacokinetics of unchanged cisplatin and nephrotoxicity after intravenous infusions of cisplatin to cancer patients. Cancer Chemother Pharmacol 39:131
21. Nagai N, Ogata H, Wada Y, Tsujino D, Someya K, Ohno T, Masuhara K, Tanaka Y, Takahashi H, Nagai H, Kato K, Koshiba Y, Igarashi T, Yokoyama A, Kinameri K, Kato T, Kurita Y (1998) Population pharmacokinetics and pharmacodynamics of cisplatin in patients with cancer: analysis with the NONMEM program. J Clin Pharmacol 38:1025
22. O'Dwyer PJ, Stevenson JP, Johnson SW (2000) Clinical pharmacokinetics and administration of established platinum drugs. Drugs 59 [Suppl 4]:19
23. Planting AST, van der Burg MEL, de Boer-Dennert M, Stoter G, Verweij J (1993) Phase I/II study of a short course of weekly cisplatin in patients with advanced solid tumours. Br J Cancer 68:789
24. Pronk LC, Schellens JHM, Planting AST, van den Bent MJ, Hilkens P, van der Burg MEL, de Boer-Dennert M, Ma J, Blanc C, Harteveld M, Bruno R, Stoter G, Verweij J (1997) Phase I and pharmacologic study of docetaxel and cisplatin in patients with advanced solid tumors. J Clin Oncol 15:1071
25. Reece PA, Stafford I, Russell J, Khan M, Gill PG (1987) Creatinine clearance as a predictor of ultrafilterable platinum disposition in cancer patients treated with cisplatin: relationship between peak ultrafilterable platinum plasma levels and nephrotoxicity. J Clin Oncol 5:304
26. Reece PA, Stafford I, Davy M, Morris R, Freeman S (1989) Influence of infusion time on unchanged cisplatin disposition in patients with ovarian cancer. Cancer Chemother Pharmacol 24:256
27. Reece PA, Stafford I, Abbott RL, Anderson C, Denham J, Freeman S, Morris RG, Gill PG, Olweny CL (1989) Two-versus 24-hour infusion of cisplatin: pharmacokinetic considerations. J Clin Oncol 7:270
28. Schellens JHM, Ma J, Planting AST, van der Burg MEL, de Boer-Dennert M, Stoter G, Verweij J (1995) Individualization of cisplatin chemotherapy using AUC and DNA-adducts in WBC (abstract 1388). Proc Am Assoc Cancer Res 36:421
29. Schellens JHM, Ma J, Planting AST, van der Burg MEL, van Meerten E, de Boer-Dennert M, Schmitz PI, Stoter G, Verweij J (1996) Relationship between the exposure to cisplatin, DNA-adduct formation in leucocytes and tumour response in patients with solid tumours. Br J Cancer 73:1569
30. Schellens JHM, Planting AST, Ma J, Maliepaard M, de Vos A, de Boer-Dennert M, Verweij J (2001) Adaptive intrapatient dose escalation of cisplatin in patients with advanced head and neck cancer. Anticancer Drugs 12:667
31. Stewart DJ, Dulberg CS, Mikhael NZ, Redmond MD, Montpetit VA, Goel R (1997) Association of cisplatin nephrotoxicity with patient characteristics and cisplatin administration methods. Cancer Chemother Pharmacol 40:293